Appendix 4 PBS listed pharmaceuticals (by drug) for the treatment of diseases of bone structure and mineralisation Drug strength Indication Specific indication BMD / code Bisphosphonates Alendronate 40 mg 3256 Symptomatic Paget disease of bone N/A Sodium alendronic acid 70 mg 4122 Corticosteroid-induced osteoporosis in a patient currently on long-term (≥ 3 months), high-dose (7.5 ≤-1.5 alendronic mg/day prednisolone or equivalent) corticosteroid therapy. acid Patient must not receive concomitant treatment with any other PBS-subscribed anti-resorptive agent for this condition. Duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient’s medical records when treatment is initiated. 4133 Osteoporosis in a patient aged 70 or older. ≤-2.5 Patient must not receive concomitant treatment with any PBS-subscribed anti-resorptive agent for this condition. Date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient’s medical records when treatment is initiated. 4123 Established osteoporosis in a patient with fracture due to minimal trauma. N/A Patient must not receive concomitant treatment with any other PBS-subscribed anti-resorptive agent for this condition. Fracture must have been demonstrated radiologically and the year of plain x-ray, CT or MRI scan must be documented in the patient’s medical records when treatment is initiated.
Appendix 4 PBS listed pharmaceuticals (by drug) for the treatment of diseases of bone structure and mineralisation Drug strength Indication code Specific indication BMD / Bisphosphonates Alendronate Sodium 40 mg alendronic acid 3256 Symptomatic Paget disease of bone N/A 70 mg alendronic acid 4122 Corticosteroid-induced osteoporosis in a patient currently on long-term (≥ 3 months), high-dose (7.5 mg/day prednisolone or equivalent) corticosteroid therapy. Patient must not receive concomitant treatment with any other PBS-subscribed anti-resorptive agent for this condition. Duration and dose of corticosteroid therapy together with the date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient’s medical records when treatment is initiated. ≤-1.5 4133 Osteoporosis in a patient aged 70 or older. Patient must not receive concomitant treatment with any PBS-subscribed anti-resorptive agent for this condition. Date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient’s medical records when treatment is initiated. ≤-2.5 4123 Established osteoporosis in a patient with fracture due to minimal trauma. Patient must not receive concomitant treatment with any other PBS-subscribed anti-resorptive agent for this condition. Fracture must have been demonstrated radiologically and the year of plain x-ray, CT or MRI scan must be documented in the patient’s medical records when treatment is initiated. N/A
App1248-FinalDAP-acessible.docx